MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers

MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers

Biliary tract cancers (BTCs) have poor prognosis and limited therapeutic options. The impact of O6‐methylguanine‐DNA methyltransferase (MGMT) inactivation in advanced BTC patients is not established. We investigated the prevalence, prognostic, and predictive impact of MGMT inactivation in two multic...

Full description

Bibliographic Details
Main Authors: Monica Niger, Federico Nichetti, Andrea Casadei‐Gardini, Federica Morano, Chiara Pircher, Elena Tamborini, Federica Perrone, Matteo Canale, Daniel B. Lipka, Andrea Vingiani, Luca Agnelli, Anna Dobberkau, Jennifer Hüllein, Felix Korell, Christoph E. Heilig, Sara Pusceddu, Francesca Corti, Michele Droz, Paola Ulivi, Michele Prisciandaro, Maria Antista, Marta Bini, Laura Cattaneo, Massimo Milione, Hanno Glimm, Bruno C. Köhler, Giancarlo Pruneri, Daniel Hübschmann, Stefan Fröhling, Vincenzo Mazzaferro, Filippo Pietrantonio, Maria Di Bartolomeo, Filippo deBraud
Format: Article
Language:English
Published: Wiley 2022-07-01
Series:Molecular Oncology
Subjects:
biliary tract cancer
biomarker
cholangiocarcinoma
MGMT
molecular profiling
temozolomide
Online Access:https://doi.org/10.1002/1878-0261.13256

Internet

https://doi.org/10.1002/1878-0261.13256

Similar Items